No quarterly revenue total was found in ACTUATE THERAPEUTICS, INC.'s SEC filings.
Actuate Therapeutics, Inc. (ACTU) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-4.87M
+18.2% vs year-ago quarter
Operating cash flow
$-4.41M
-5.5% vs year-ago quarter
Free cash flow
—
EPS
$-0.20
+33.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
24.01M
+15.8% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACTU (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Fort Worth, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1652935
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$4.9M | -$5.7M | -$4.7M | -$5.5M | -$6.0M |
| Net income | -$4.9M | -$5.6M | -$4.6M | -$5.4M | -$5.9M |
| Diluted EPS | -$0.20 | -$0.24 | -$0.19 | -$0.25 | -$0.30 |
| Operating cash flow | -$4.4M | -$5.0M | -$3.7M | -$6.7M | -$4.2M |
| Total assets | $5.2M | $8.9M | $14.0M | $17.7M | $7.0M |
| Total liabilities | $4.2M | $5.1M | $6.1M | $6.8M | $9.6M |
| Stockholders' equity | $989,152 | $3.8M | $7.9M | $10.9M | -$2.7M |
| Cash and investments | $4.4M | $8.1M | $13.2M | $16.9M | $6.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice
|
Oct 30, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Oct 28, 2026 | Oct 26, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 17, 2026 | Jul 15, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 22, 2026 | May 21, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
All 192 Actuate Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.